{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:11:13Z","timestamp":1790727073555,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejca.2023.113312","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T12:28:52Z","timestamp":1693225732000},"page":"113312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7871-2142","authenticated-orcid":false,"given":"Kyoo Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minkyu","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miso","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Sun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na-Ri","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Joon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejca.2023.113312_bib1","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113312_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/OP.21.00686","article-title":"Managing metastatic melanoma in 2022: a clinical review","volume":"18","author":"Switzer","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"22","key":"10.1016\/j.ejca.2023.113312_bib3","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA J Am Med Assoc"},{"issue":"6","key":"10.1016\/j.ejca.2023.113312_bib4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1600-0463.2011.02737.x","article-title":"KIT amplification and gene mutations in acral\/mucosal melanoma in Korea","volume":"119","author":"Yun","year":"2011","journal-title":"APMIS"},{"issue":"7","key":"10.1016\/j.ejca.2023.113312_bib5","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/1078-0432.CCR-10-2346","article-title":"Large-scale analysis of KIT aberrations in Chinese patients with melanoma","volume":"17","author":"Kong","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2023.113312_bib6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/jid.2012.338","article-title":"BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas","volume":"133","author":"Jin","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"47","key":"10.1016\/j.ejca.2023.113312_bib7","doi-asserted-by":"crossref","first-page":"82661","DOI":"10.18632\/oncotarget.19746","article-title":"The clinical significance of c-Kit mutations in metastatic oral mucosal melanoma in China","volume":"8","author":"Ma","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ejca.2023.113312_bib8","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/sj.jid.5700125","article-title":"Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes","volume":"126","author":"Alexeev","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"21","key":"10.1016\/j.ejca.2023.113312_bib9","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J clin oncol"},{"issue":"26","key":"10.1016\/j.ejca.2023.113312_bib10","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113312_bib11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"issue":"9863","key":"10.1016\/j.ejca.2023.113312_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"9863","key":"10.1016\/j.ejca.2023.113312_bib13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"10064","key":"10.1016\/j.ejca.2023.113312_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2023.113312_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113312_bib16","unstructured":"Group CTE. National Cancer Institute. Common terminology criteria for adverse events v4.0 (CTCAE); 2009."},{"issue":"5","key":"10.1016\/j.ejca.2023.113312_bib17","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41416-022-01837-z","article-title":"Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment","volume":"127","author":"Kim","year":"2022","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2023.113312_bib18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113312_bib19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jid.2017.07.839","article-title":"STAT3 mediates nilotinib response in KIT-altered melanoma: a phase II multicenter trial of the French skin cancer network","volume":"138","author":"Delyon","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2023.113312_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100520","article-title":"Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma","volume":"7","author":"Janku","year":"2022","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.ejca.2023.113312_bib21","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/annonc\/mdx079","article-title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial","volume":"28","author":"Guo","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.113312_bib22","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1634\/theoncologist.2015-0161","article-title":"Phase II trial of nilotinib in patients with metastatic malignant melanoma harboring KIT gene aberration: a multicenter trial of Korean Cancer Study Group (UN10-06)","volume":"20","author":"Lee","year":"2015","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ejca.2023.113312_bib23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2023.113312_bib24","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ejca.2023.113312_bib25","doi-asserted-by":"crossref","first-page":"S919","DOI":"10.1016\/j.annonc.2022.07.941","article-title":"815P a single-arm, phase II clinical study of imatinib mesylate\/toripalimab combo in patients (pts) with advanced melanoma harboring c-Kit mutation or amplification","volume":"33","author":"Si","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113312_bib26","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.bcp.2010.04.032","article-title":"Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics","volume":"80","author":"Woodman","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ejca.2023.113312_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.672500","article-title":"Early and next-generation KIT\/PDGFRA kinase inhibitors and tHe Future of Treatment for Advanced Gastrointestinal Stromal Tumor","volume":"11","author":"Bauer","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.113312_bib28","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3349\/ymj.2020.61.7.562","article-title":"KIT and melanoma: biological insights and clinical implications","volume":"61","author":"Pham","year":"2020","journal-title":"Yonsei Med J"},{"issue":"6","key":"10.1016\/j.ejca.2023.113312_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-019-0389-6","article-title":"Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours","volume":"120","author":"Serrano","year":"2019","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2023.113312_bib30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3390\/cancers13050993","article-title":"Type and gene location of KIT mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: a look into the exon","volume":"13","author":"Incorvaia","year":"2021","journal-title":"Cancers"},{"issue":"27","key":"10.1016\/j.ejca.2023.113312_bib31","doi-asserted-by":"crossref","first-page":"44121","DOI":"10.18632\/oncotarget.17310","article-title":"A phase II trial of regorafenib in patients with metastatic and\/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17","volume":"8","author":"Yeh","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2023.113312_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-75792-1","article-title":"Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients","volume":"10","author":"Marczynski","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejca.2023.113312_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/pcmr.12623","article-title":"Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma","volume":"31","author":"Gangadhar","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"issue":"7","key":"10.1016\/j.ejca.2023.113312_bib34","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41431-018-0132-4","article-title":"Circulating cell-free nucleic acids: characteristics and applications","volume":"26","author":"P\u00f6s","year":"2018","journal-title":"Eur J\u00a0Hum Genet"},{"issue":"6","key":"10.1016\/j.ejca.2023.113312_bib35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113312_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.639233","article-title":"Cell-free DNA: hope and potential application in cancer","volume":"9","author":"Yan","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"10.1016\/j.ejca.2023.113312_bib37","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1517\/13543784.2012.684752","article-title":"Regorafenib for cancer","volume":"21","author":"Strumberg","year":"2012","journal-title":"Expert Opin Investig Drugs"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923004148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923004148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:48Z","timestamp":1760733768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923004148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":37,"alternative-id":["S0959804923004148"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113312","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113312"}}